Detailed information on the top ten drugs whose patents will expire in 2025:
1. Stelara (Johnson&Johnson)
Indications: Psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis
2024 US sales: $6.72 billion
• Sales peak: Global sales reach $10.36 billion by 2024
Background: Stelara is a heavyweight immunology drug under Johnson&Johnson, and as the patent cliff approaches, Stelara is facing fierce competition from biosimilars.
2. Eylea (Regenerative Element)
• Indications: wet age-related macular degeneration, diabetes macular edema, retinal vein occlusion, retinopathy of prematurity, diabetes retinopathy
2024 US sales: $4.77 billion
• Sales peak: Global sales reach $9.25 billion in 2022
Background: Since Roche's Vabysmo entered the market in 2022, Eylea's sales growth has stagnated.
3. Prolia/Xgeva (Anjin)
• Indications: osteoporosis, bone loss in prostate or breast cancer patients, bone related events in cancer patients with bone metastasis, giant cell tumor of bone, hypercalcemia caused by malignant tumors
2024 US sales: $4.39 billion
• Sales peak: Global sales reach 6.93 billion US dollars in 2023
Background: The main patents for these two drugs have expired in February 2025.
4. Entresto (Novartis)
Indication: Heart failure
2024 US sales: $4.05 billion
• Sales peak: Global sales reach 5.52 billion US dollars in 2023
Background: With its key combination patents expiring in July 2025, Entresto may lose its exclusive rights to the US market by mid-2025.
5. Soliris (AstraZeneca)
Indications: Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Systemic Myasthenia Gravis, Neuromyelitis Spectrum Disorder
2024 US sales: 1.52 billion US dollars
• Sales peak: Global sales reach 2.59 billion US dollars in 2023
Background: Soliris has enjoyed nearly 20 years of market exclusivity since its approval in 2007, but now faces the threat of biosimilars.
6. Promacta (Novartis)
Indications: thrombocytopenia, aplastic anemia
2024 US sales: $1.18 billion
• Sales peak: Global sales reach 1.85 billion US dollars in 2023
Background: The patent protection for this drug has expired in 2024 and is expected to face competition from generic drugs by mid-2025.
7. Simponi/Simponi Aria (Johnson&Johnson)
Indications: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, polyarticular juvenile idiopathic arthritis
2024 US sales: $1.08 billion
• Sales peak: Global sales reached 2.28 billion US dollars in 2021
Background: Its substance composition patent expires in 2024, and it is expected that the first biosimilar drug will receive FDA approval and be launched in the fourth quarter of 2025.
8. Tysabri (Bo Jian)
Indications: Multiple sclerosis, Crohn's disease
2024 US sales: $920 million
• Sales peak: Global sales reach 1.56 billion US dollars in 2023
Background: Tysabri's patent protection has expired in 2024.
9. Brilinta (AstraZeneca)
Indications: Acute coronary syndrome, coronary heart disease, acute ischemic stroke, or high-risk transient ischemic attack
2024 US sales: $751 million
• Sales peak: Global sales reach 1.23 billion US dollars in 2023
Background: In 2025, Brilinta is expected to face competition from generic drugs.
10. Farxiga (AstraZeneca)
• Indications: type 2 diabetes, heart failure, chronic kidney disease
2024 US sales: $5.96 billion
• Sales peak: Global sales reach $6.5 billion by 2023
Background: Farxiga's patent protection will expire in February 2025.
The expiration of market exclusivity for these heavyweight drugs not only brings about price competition, but may also change the market landscape. Pharmaceutical companies need to plan ahead and address challenges by developing new drugs, expanding markets, or promoting future drugs. For investors and patients, this means more choices and lower medication costs.
<Reprinted from Drug Hunter>
